| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
TLR9
CpG ODN 10101 targets Toll-like receptor 9 (TLR9), which is expressed on plasmacytoid dendritic cells and B cells. TLR9 recognizes unmethylated CpG DNA motifs, which are common in bacterial and viral DNA but rare in vertebrate DNA. Activation of TLR9 by CpG ODN 10101 triggers signaling cascades that lead to the production of pro-inflammatory cytokines and the activation of immune cells. |
|---|---|
| ln Vitro |
CpG ODN 10101 demonstrates potent in vitro immunostimulatory activity. It activates TLR9 signaling, leading to the production of pro-inflammatory cytokines such as IFN-α, IL-6, and TNF-α. The compound promotes the activation and maturation of dendritic cells and B cells. Its activity is assessed in cell-based assays measuring cytokine production and immune cell activation.
|
| ln Vivo |
In vivo activity of CpG ODN 10101 has been demonstrated in animal models, where it acts as a potent immunostimulatory agent. It is used as a vaccine adjuvant to enhance immune responses to co-administered antigens. The compound has been studied in models of cancer immunotherapy and infectious diseases.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for CpG ODN 10101 involve measuring its binding to TLR9 using surface plasmon resonance or other binding assays. TLR9 activation is assessed by measuring downstream signaling events such as NF-κB activation or cytokine production in TLR9-expressing cells.
|
| Cell Assay |
In vitro cellular assays for CpG ODN 10101 involve treating TLR9-expressing cells (e.g., plasmacytoid dendritic cells, B cells) with varying concentrations of the oligonucleotide. Cytokine production (e.g., IFN-α, IL-6, TNF-α) is measured using ELISA. Immune cell activation is assessed by measuring cell surface marker expression using flow cytometry.
|
| Animal Protocol |
In vivo animal experiments for CpG ODN 10101 involve administering the oligonucleotide to animal models (e.g., mice) to evaluate its immunostimulatory effects. The compound is often used as a vaccine adjuvant, and immune responses to co-administered antigens are measured. Efficacy is assessed by measuring cytokine levels, antibody responses, and immune cell activation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for CpG ODN 10101 are limited. As an oligonucleotide, its absorption, distribution, metabolism, and excretion properties would be influenced by its size and charge. The compound is typically administered by injection. Its stability and biodistribution are important considerations for its use as an immunostimulatory agent.
|
| Toxicity/Toxicokinetics |
Toxicological data for CpG ODN 10101 are limited. As an immunostimulatory agent, it may cause inflammatory responses at high doses. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
CpG ODN 10101 (ODN 10101) (CAS#: 1234402-77-7) is a synthetic oligodeoxynucleotide containing unmethylated CpG motifs. It is a TLR9 agonist used as an immunostimulatory agent in research on vaccine adjuvants, cancer immunotherapy, and infectious diseases. It induces pro-inflammatory cytokine production and activates antigen-presenting cells. It is for research use only.
|
| Molecular Weight |
6702.37
|
|---|---|
| CAS # |
1234402-77-7
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 25 mg/mL (3.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.1492 mL | 0.7460 mL | 1.4920 mL | |
| 5 mM | 0.0298 mL | 0.1492 mL | 0.2984 mL | |
| 10 mM | 0.0149 mL | 0.0746 mL | 0.1492 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
